Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Orchard Therapeutics Plc ADR (ORTX)
Orchard Therapeutics Plc ADR (ORTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 380,109
  • Shares Outstanding, K 22,761
  • Annual Sales, $ 22,660 K
  • Annual Income, $ -150,660 K
  • 60-Month Beta 0.55
  • Price/Sales 13.17
  • Price/Cash Flow N/A
  • Price/Book 4.73
Trade ORTX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.94
  • Most Recent Earnings $-0.15 on 11/13/23
  • Latest Earnings Date 03/04/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 3.06%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -2.10
  • Number of Estimates 1
  • High Estimate -2.10
  • Low Estimate -2.10
  • Prior Year -0.60
  • Growth Rate Est. (year over year) -250.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.38 +1.95%
on 01/03/24
16.72 -0.12%
on 01/23/24
+0.28 (+1.71%)
since 12/22/23
3-Month
15.78 +5.83%
on 10/31/23
16.72 -0.12%
on 01/23/24
+0.72 (+4.51%)
since 10/23/23
52-Week
4.24 +293.87%
on 03/20/23
16.72 -0.12%
on 01/23/24
+10.41 (+165.50%)
since 01/23/23

Most Recent Stories

More News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHS, SLGC, ORTX

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

CHS : 7.59 (-0.13%)
SLGC : 2.10 (-4.55%)
ORTX : 16.70 (+0.30%)
Stocks End Slightly Lower Ahead of Friday’s Monthly U.S. Payroll Report

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Thursday closed down -0.13%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.03%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed...

$SPX : 5,069.76 (-0.17%)
SPY : 506.26 (-0.13%)
$DOWI : 38,949.02 (-0.06%)
DIA : 389.60 (-0.02%)
$IUXX : 17,874.50 (-0.54%)
QQQ : 435.27 (-0.53%)
TAP : 62.89 (+0.21%)
MDLZ : 73.19 (+0.08%)
PEP : 167.03 (-0.67%)
KDP : 30.03 (+1.80%)
MNST : 55.85 (-0.46%)
KO : 60.40 (+0.10%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SP, ORTX, SUM

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

SP : 51.31 (-0.37%)
ORTX : 16.70 (+0.30%)
SUM : 42.39 (-0.47%)
Why Orchard Therapeutics Stock Is Soaring Today

A buyout offer is fueling a rise in the company's shares today.

KYKOF : 16.0216 (-2.17%)
ORTX : 16.70 (+0.30%)
Stocks Move Lower as Bond Yields Firm

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is down -0.75%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.41%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.25%....

$SPX : 5,069.76 (-0.17%)
SPY : 506.26 (-0.13%)
$DOWI : 38,949.02 (-0.06%)
DIA : 389.60 (-0.02%)
$IUXX : 17,874.50 (-0.54%)
QQQ : 435.27 (-0.53%)
CLX : 153.48 (+1.05%)
ZBRA : 272.80 (-1.08%)
ABNB : 153.43 (+0.90%)
STZ : 247.44 (+0.14%)
RIVN : 11.30 (+1.44%)
RGP : 13.61 (-0.95%)
Markets Today: Stocks Slip as Bond Yields Climb on U.S. Labor Market Strength

Morning Markets December E-Mini S&P 500 futures (ESZ2 3) are down -0.39%, and the Dec Nasdaq 100 E-Mini futures (NQZ2 3) are down -0.34%. Stock index futures this morning are moderately lower. A smaller-than-expected...

ESH24 : 5,080.25 (-0.01%)
NQH24 : 17,907.50 (-0.04%)
CLX : 153.48 (+1.05%)
RIVN : 11.30 (+1.44%)
TSCO : 252.60 (+0.56%)
DVN : 44.03 (-0.65%)
PSX : 141.24 (-2.82%)
HAL : 34.95 (-0.03%)
MRO : 24.12 (-0.70%)
SLB : 48.16 (-0.62%)
XOM : 104.32 (+0.28%)
OXY : 60.26 (-0.56%)
Are Gene Therapy Stocks The Market's Next Big Winners?

Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.

SRPT : 137.50 (-2.85%)
BMRN : 88.40 (-2.51%)
BIIB : 221.74 (-0.98%)
CRSP : 87.68 (-1.62%)
EDIT : 11.07 (+24.94%)
NTLA : 32.80 (+5.74%)
NVS : 102.22 (-0.90%)
ORTX : 16.70 (+0.30%)
REGN : 987.61 (-0.58%)
SLDB : 9.45 (-6.25%)
BLUE : 1.6800 (-4.00%)
Orchard Therapeutics Reports Second Quarter 2022 Financial Results and Reviews Recent Business Highlights

Additional Libmeldy® reimbursement discussions advancing across Europe with product sales totaling $3.1M in Q2 and $8.2M YTD OTL-200 U.S. BLA filing for...

ORTX : 16.70 (+0.30%)
Orchard Therapeutics Announces Reimbursement Agreement Making Libmeldy Available for All Eligible MLD Patients in Italy

BOSTON and LONDON, April 11, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced it has reached...

ORTX : 16.70 (+0.30%)
Orchard Therapeutics Extends Runway into 2024, Focusing HSC Gene Therapy Platform Exclusively on Severe Neurometabolic Diseases and Research Platform

Libmeldy European launch momentum building with multiple MLD patients treated and strong recognition of value proposition; U.S. BLA filing of OTL-200 on...

ORTX : 16.70 (+0.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Orchard Therapeutics plc is a biopharmaceutical company. It offers medical research, gene therapy and inherited disorder treatment services which transforms the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. Orchard Therapeutics plc is based...

See More

Key Turning Points

3rd Resistance Point 16.83
2nd Resistance Point 16.77
1st Resistance Point 16.74
Last Price 16.70
1st Support Level 16.65
2nd Support Level 16.59
3rd Support Level 16.56

See More

52-Week High 16.72
Last Price 16.70
Fibonacci 61.8% 11.95
Fibonacci 50% 10.48
Fibonacci 38.2% 9.01
52-Week Low 4.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar